An observational study in Heart Valve Diseases, Multiple Valve Disease, Unspecified and Aortic Valve Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.
Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 5th largest by planned enrollment of the 17 observational ones that give a count, is one of 6 that started in 2024, is one of 17 observational ones, reaches primary completion later than 3 of the 21 other live ones, and was the 42nd registered.
556 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
French Cardiology Society · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+ · Healthy volunteers
Abbott Medical Devices · Sites in France, United States, Denmark and 7 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3
First in 2002; this study’s year is marked. 6 started in 2024.
This study's planned enrollment of 1,500 is above the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 228 across the 31 interventional studies, 800 across the 17 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 48 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 2 studies filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Valve Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06215378Phase 3Assistance Publique - Hôpitaux de ParisAntagonization of Heparin With Protamine Sulfate After TAVI | 2027-03-01 |
| NCT02747485Assistance Publique Hopitaux De MarseilleImpact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study) | 2026-11 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Valve Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.
Multiple and mixed valvular heart disease (MMVD), ie, the combination of stenotic or regurgitant lesions occurring on ≥2 cardiac valves (multiple valvular heart disease (VHD)) or the combination of stenotic and regurgitant lesions on the same valve (mixed VHD), are frequent in clinical routine. Nevertheless, their clinical, biological, cardiovascular imaging, and management is not well established.
This study will assess the proportion of MMVD including each combination of multiple and mixed VHD in a multicentre registry of all consecutive patients assessed on a cardiovascular imaging department for VHD. Furthermore, as secondary aims, baseline characteristics, decision-making and therapeutic strategy at baseline and their impact in terms of prognostic.
This is a prospective multicentre observational study involving 174 centres worldwide (35 countries) conducted as a cohort study with a 1-year follow-up (with possible extension to 5 years). Consecutive patients with a diagnosis of MMVD by echocardiography who meet the inclusion criteria will be included during the 6 months period of recruitment. In the context of a "real-life" cohort, baseline evaluation will be left to the discretion of the attending physician (and could encompass clinical evaluations, biomarkers, electrocardiograms, transthoracic and transoesophageal echocardiography, stress echocardiography, cardiac catheterization, invasive angiography, cardiac CT, and Cardiac MRI). Final diagnosis of the physician will be given, and physician will manage the patient in accordance with international guidelines (transcatheter valve intervention, surgery or no intervention). One year follow-up will be performed during a patient visit or by contact with the treating physician or the patient: vital status, hospitalizations for cardiac reasons (including heart failure), history of stroke and the performance of a new valvular intervention.
The primary endpoint will be the proportion of MMVD among all patients admitted for VHD evaluation in the imaging department. Secondary endpoints encompass; (i) epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline. (ii) proportion of MMVD treated by surgery, percutaneous or medical as well as the detail for management and how complication are managed (iii) prognostic evaluation at one year of follow-up in terms of clinical composite outcome (cardiovascular mortality, hospitalization for heart failure, myocardial infarction, pulmonary embolism and stroke), all-cause mortality, hospitalisation for heart failure, and change in echocardiographic parameters.
This is the first prospective multicentre study assessing the proportion of MMVD and their characteristics in term of diagnosis, management, and prognostic.
All patients referred to a Cardiovascular imaging Department with a diagnosis of at least one at least moderate VHD, and who meet the criteria for MMVD defined by multiple and/or mixed disease, will be included in the study.
Inclusion Criteria:
Diagnosis of MMVD confirmed by transthoracic echocardiography, defined as:
Multiple VHD: at least 2 moderates to severe VHD involving ≥ 2 different valves, using the current ESC guidelines.
and/or
Exclusion Criteria (patients fulfilling any of the following criteria are not eligible for inclusion in this study):
This study is purely observational
Proportion of multiple and mixed valvular disease (MMVD)
Number of consecutive patients diagnosed with multiple and mixed valvular disease divided by the total number of consecutive patients assessed for valvular heart disease on a cardiovascular imaging department
Time frame: Baseline
Major Adverse Cardiovascular Event (MACE)
Clinical composite outcome defined as: cardiovascular mortality, hospitalization for heart failure (HF), myocardial infarction, pulmonary embolism and stroke.
Time frame: Up to 5 years
All-cause mortality
The adjudication of all-cause death was performed using the follow-up performed in clinical routine
Time frame: Up to 5 years
Cardiovascular mortality
The adjudication of cardiovascular mortality was performed using the follow-up performed in clinical routine
Time frame: Up to 5 years
Hospitalization for heart failure
Hospitalization for heart failure according to the European Society of Cardiology (ESC) guidelines
Time frame: Up to 5 years
Plan to share: No — Data cannot be shared for ethical/privacy reasons. The data cannot be shared publicly for the privacy of individuals that participated in the study and also because of regulatory constraints in the field of clinical research in France, it is unfortunately not possible to make the entire database available to all as an open source.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Aug 2024, 5 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 5 months is below that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →